• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LRRK2 与脂质代谢通路:帕金森病的相关影响。

LRRK2 and Lipid Pathways: Implications for Parkinson's Disease.

机构信息

Charles Perkins Centre and Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, NSW 2050, Australia.

Brain and Mind Centre and Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, NSW 2050, Australia.

出版信息

Biomolecules. 2022 Oct 30;12(11):1597. doi: 10.3390/biom12111597.

DOI:10.3390/biom12111597
PMID:36358947
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9687231/
Abstract

Genetic alterations in the gene, encoding leucine-rich repeat kinase 2, are a common risk factor for Parkinson's disease. How LRRK2 alterations lead to cell pathology is an area of ongoing investigation, however, multiple lines of evidence suggest a role for LRRK2 in lipid pathways. It is increasingly recognized that in addition to being energy reservoirs and structural entities, some lipids, including neural lipids, participate in signaling cascades. Early investigations revealed that LRRK2 localized to membranous and vesicular structures, suggesting an interaction of LRRK2 and lipids or lipid-associated proteins. LRRK2 substrates from the Rab GTPase family play a critical role in vesicle trafficking, lipid metabolism and lipid storage, all processes which rely on lipid dynamics. In addition, LRRK2 is associated with the phosphorylation and activity of enzymes that catabolize plasma membrane and lysosomal lipids. Furthermore, LRRK2 knockout studies have revealed that blood, brain and urine exhibit lipid level changes, including alterations to sterols, sphingolipids and phospholipids, respectively. In human LRRK2 mutation carriers, changes to sterols, sphingolipids, phospholipids, fatty acyls and glycerolipids are reported in multiple tissues. This review summarizes the evidence regarding associations between LRRK2 and lipids, and the functional consequences of LRRK2-associated lipid changes are discussed.

摘要

基因中的遗传改变,编码富含亮氨酸重复激酶 2,是帕金森病的一个常见危险因素。LRRK2 改变如何导致细胞病理学是一个正在进行的研究领域,然而,多条证据表明 LRRK2 在脂质途径中起作用。人们越来越认识到,除了作为能量储备和结构实体外,一些脂质,包括神经脂质,参与信号级联反应。早期的研究表明,LRRK2 定位于膜和囊泡结构,提示 LRRK2 与脂质或脂质相关蛋白相互作用。Rab GTPase 家族的 LRRK2 底物在囊泡运输、脂质代谢和脂质储存中发挥关键作用,所有这些过程都依赖于脂质动力学。此外,LRRK2 与分解质膜和溶酶体脂质的酶的磷酸化和活性有关。此外,LRRK2 敲除研究表明,血液、大脑和尿液显示脂质水平变化,分别包括固醇、鞘脂和磷脂的改变。在人类 LRRK2 突变携带者中,在多种组织中报告了固醇、鞘脂、磷脂、脂肪酸和甘油脂质的改变。本综述总结了 LRRK2 与脂质之间的关联的证据,并讨论了与 LRRK2 相关的脂质变化的功能后果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/334d/9687231/ed151aaeb810/biomolecules-12-01597-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/334d/9687231/1b401e00d8cf/biomolecules-12-01597-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/334d/9687231/8e63390442da/biomolecules-12-01597-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/334d/9687231/ed151aaeb810/biomolecules-12-01597-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/334d/9687231/1b401e00d8cf/biomolecules-12-01597-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/334d/9687231/8e63390442da/biomolecules-12-01597-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/334d/9687231/ed151aaeb810/biomolecules-12-01597-g003.jpg

相似文献

1
LRRK2 and Lipid Pathways: Implications for Parkinson's Disease.LRRK2 与脂质代谢通路:帕金森病的相关影响。
Biomolecules. 2022 Oct 30;12(11):1597. doi: 10.3390/biom12111597.
2
The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.帕金森病 VPS35[D620N]突变增强了小鼠和人类中 LRRK2 介导的 Rab 蛋白磷酸化。
Biochem J. 2018 Jun 6;475(11):1861-1883. doi: 10.1042/BCJ20180248.
3
The Role of LRRK2 in Intracellular Organelle Dynamics.LRRK2 在细胞内细胞器动态中的作用。
J Mol Biol. 2023 Jun 15;435(12):167998. doi: 10.1016/j.jmb.2023.167998. Epub 2023 Feb 9.
4
LRRK2 and Rab GTPases.LRRK2 和 Rab GTPases。
Biochem Soc Trans. 2018 Dec 17;46(6):1707-1712. doi: 10.1042/BST20180470. Epub 2018 Nov 22.
5
Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes.Rab12是LRRK2的调节剂,且其由受损溶酶体激活。
Elife. 2023 Oct 24;12:e87255. doi: 10.7554/eLife.87255.
6
Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.LRRK2 导致 Rab GTPases 的磷酸化失调,从而引发神经退行性变。
Mol Neurodegener. 2018 Feb 13;13(1):8. doi: 10.1186/s13024-018-0240-1.
7
Lipid pathway dysfunction is prevalent in patients with Parkinson's disease.脂代谢途径紊乱在帕金森病患者中普遍存在。
Brain. 2022 Oct 21;145(10):3472-3487. doi: 10.1093/brain/awac176.
8
LRRK2 phosphorylation of Rab GTPases in Parkinson's disease.LRRK2 对帕金森病中 Rab GTPases 的磷酸化作用。
FEBS Lett. 2023 Mar;597(6):811-818. doi: 10.1002/1873-3468.14492. Epub 2022 Sep 26.
9
Insights into the cellular consequences of LRRK2-mediated Rab protein phosphorylation.LRRK2 介导的 Rab 蛋白磷酸化对细胞后果的深入了解。
Biochem Soc Trans. 2023 Apr 26;51(2):587-595. doi: 10.1042/BST20201145.
10
Cellular effects mediated by pathogenic LRRK2: homing in on Rab-mediated processes.致病性LRRK2介导的细胞效应:聚焦于Rab介导的过程。
Biochem Soc Trans. 2017 Feb 8;45(1):147-154. doi: 10.1042/BST20160392.

引用本文的文献

1
Lipid metabolism in health and disease: Mechanistic and therapeutic insights for Parkinson's disease.健康与疾病中的脂质代谢:帕金森病的机制与治疗见解
Chin Med J (Engl). 2025 Jun 20;138(12):1411-1423. doi: 10.1097/CM9.0000000000003627. Epub 2025 May 26.
2
Lipid Metabolism and Statin Therapy in Neurodegenerative Diseases: An Endocrine View.神经退行性疾病中的脂质代谢与他汀类药物治疗:内分泌视角
Metabolites. 2025 Apr 18;15(4):282. doi: 10.3390/metabo15040282.
3
In silico fragment-based discovery of CIB1-directed anti-tumor agents by FRASE-bot.

本文引用的文献

1
Brain lipidomics: From functional landscape to clinical significance.脑脂质组学:从功能图谱到临床意义。
Sci Adv. 2022 Sep 16;8(37):eadc9317. doi: 10.1126/sciadv.adc9317.
2
LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease.在帕金森病中,LRRK2激酶活性根据细胞类型不同,对葡萄糖脑苷脂酶(GCase)水平和酶活性的调节也不同。
NPJ Parkinsons Dis. 2022 Jul 19;8(1):92. doi: 10.1038/s41531-022-00354-3.
3
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
基于 FRASE-bot 的基于片段的计算机虚拟筛选发现 CIB1 定向抗肿瘤剂。
Nat Commun. 2024 Jul 2;15(1):5564. doi: 10.1038/s41467-024-49892-9.
4
Prediction of motor and non-motor Parkinson's disease symptoms using serum lipidomics and machine learning: a 2-year study.利用血清脂质组学和机器学习预测帕金森病的运动和非运动症状:一项为期两年的研究。
NPJ Parkinsons Dis. 2024 Jun 25;10(1):123. doi: 10.1038/s41531-024-00741-y.
5
Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results.颗粒蛋白前体 AAV 基因治疗额颞叶痴呆:转化研究和 1/2 期试验中期结果。
Nat Med. 2024 May;30(5):1406-1415. doi: 10.1038/s41591-024-02973-0. Epub 2024 May 14.
6
The marine-derived compound TAG alleviates Parkinson's disease by restoring RUBCN-mediated lipid metabolism homeostasis.海洋来源化合物 TAG 通过恢复 RUBCN 介导的脂代谢平衡缓解帕金森病。
Acta Pharmacol Sin. 2024 Jul;45(7):1366-1380. doi: 10.1038/s41401-024-01259-y. Epub 2024 Mar 27.
7
Nigral transcriptomic profiles in Engrailed-1 hemizygous mouse models of Parkinson's disease reveal upregulation of oxidative phosphorylation-related genes associated with delayed dopaminergic neurodegeneration.帕金森病的Engrailed-1半合子小鼠模型中的黑质转录组图谱揭示了与多巴胺能神经变性延迟相关的氧化磷酸化相关基因的上调。
Front Aging Neurosci. 2024 Feb 5;16:1337365. doi: 10.3389/fnagi.2024.1337365. eCollection 2024.
8
Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson's Disease.遗传与生化研究进展:揭示帕金森病神经退行性变的病因发病机制。
Biomolecules. 2024 Jan 5;14(1):73. doi: 10.3390/biom14010073.
9
Gasdermins assemble; recent developments in bacteriology and pharmacology.Gasdermins 组装;细菌学和药理学的最新进展。
Front Immunol. 2023 May 17;14:1173519. doi: 10.3389/fimmu.2023.1173519. eCollection 2023.
10
Changes in Liver Lipidomic Profile in G2019S- Mouse Model of Parkinson's Disease.G2019S 突变型帕金森病小鼠模型中肝脏脂质组学谱的变化。
Cells. 2023 Mar 4;12(5):806. doi: 10.3390/cells12050806.
DLN201 作为 LRRK2 抑制剂用于帕金森病的临床前和临床评估。
Sci Transl Med. 2022 Jun 8;14(648):eabj2658. doi: 10.1126/scitranslmed.abj2658.
4
Lipid pathway dysfunction is prevalent in patients with Parkinson's disease.脂代谢途径紊乱在帕金森病患者中普遍存在。
Brain. 2022 Oct 21;145(10):3472-3487. doi: 10.1093/brain/awac176.
5
Variants and Parkinson Disease: Mechanisms and Treatments.变异与帕金森病:机制与治疗。
Cells. 2022 Apr 8;11(8):1261. doi: 10.3390/cells11081261.
6
Assessment of Glucocerebrosidase Enzyme Activity in Parkinson Disease Using Multiple Approaches.使用多种方法评估帕金森病中的葡萄糖脑苷脂酶活性
Mov Disord. 2022 Mar;37(3):655-656. doi: 10.1002/mds.28951. Epub 2022 Feb 1.
7
Mini-review: Synaptojanin 1 and its implications in membrane trafficking.综述:突触结合蛋白 1 及其在膜转运中的作用。
Neurosci Lett. 2021 Nov 20;765:136288. doi: 10.1016/j.neulet.2021.136288. Epub 2021 Oct 9.
8
Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity.溶酶体葡萄糖脑苷脂酶活性测定策略的评估。
Mov Disord. 2021 Dec;36(12):2719-2730. doi: 10.1002/mds.28815. Epub 2021 Oct 6.
9
Lipid Metabolite Biomarkers in Cardiovascular Disease: Discovery and Biomechanism Translation from Human Studies.心血管疾病中的脂质代谢物生物标志物:来自人体研究的发现与生物机制转化
Metabolites. 2021 Sep 14;11(9):621. doi: 10.3390/metabo11090621.
10
Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.葡萄糖脑苷脂酶活性与帕金森病风险或严重程度无关。
Mov Disord. 2022 Jan;37(1):190-195. doi: 10.1002/mds.28792. Epub 2021 Sep 22.